Susceptibilities of Ugandan Plasmodium falciparum Isolates to Proteasome Inhibitors-Reference-Cited by-同舟云学术

Susceptibilities of Ugandan Plasmodium falciparum Isolates to Proteasome Inhibitors

Published:2022-10-18 Issue:10 Volume:66 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Garg Shreeya¹,Kreutzfeld Oriana¹^ORCID,Chelebieva Sevil²,Tumwebaze Patrick K.³,Byaruhanga Oswald³,Okitwi Martin³,Orena Stephen³,Katairo Thomas³,Nsobya Samuel L.³,Conrad Melissa D.¹^ORCID,Aydemir Ozkan⁴,Legac Jennifer¹,Gould Alexandra E.⁵,Bayles Brett R.²,Bailey Jeffrey A.⁶,Duffey Maelle⁷,Lin Gang⁸,Kirkman Laura A.⁸⁹^ORCID,Cooper Roland A.²^ORCID,Rosenthal Philip J.¹^ORCID

Affiliation:

1. Department of Medicine, University of California, San Francisco, California, USA

2. Department of Natural Sciences and Mathematics, Dominican University of California, San Rafael, California, USA

3. Infectious Diseases Research Collaboration, Kampala, Uganda

4. Program in Molecular Medicine, University of Massachusetts, Worcester, Massachusetts, USA

5. Takeda Pharmaceuticals, Cambridge, Massachusetts, USA

6. Department of Pathology and Laboratory Medicine, Brown University, Providence, Rhode Island, USA

7. Medicines for Malaria Venture, Geneva, Switzerland

8. Department of Microbiology and Immunology, Weill Cornell Medicine, New York, New York, USA

9. Department of Medicine, Weill Cornell Medicine, New York, New York, USA

Abstract

The proteasome is a promising target for antimalarial chemotherapy. We assessed ex vivo susceptibilities of fresh Plasmodium falciparum isolates from eastern Uganda to seven proteasome inhibitors: two asparagine ethylenediamines, two macrocyclic peptides, and three peptide boronates; five had median IC 50 values <100 nM.

Funder

HHS | NIH | NIAID | Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases

HHS | NIH | National Institute on Minority Health and Health Disparities

Medicines for Malaria Venture

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/aac.00817-22

Reference27 articles.

1. World Health Organization. 2021. World malaria report 2021. World Health Organization Geneva. https://apps.who.int/iris/handle/10665/350147. Retrieved 4 March 2022.

2. The proteasome: Overview of structure and functions

3. Proteasome Inhibitors and Their Pharmacokinetics, Pharmacodynamics, and Metabolism

4. Microbial proteasomes as drug targets

5. Structure characterization of the 26S proteasome

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Susceptibility of Ugandan Plasmodium falciparum Isolates to the Antimalarial Drug Pipeline;Microbiology Spectrum;2023-06-15

2. Dual-pharmacophore artezomibs hijack the Plasmodium ubiquitin-proteasome system to kill malaria parasites while overcoming drug resistance;Cell Chemical Biology;2023-05

3. Mitigating the risk of antimalarial resistance via covalent dual-subunit inhibition of the Plasmodium proteasome;Cell Chemical Biology;2023-05

4. Proteasome inhibitors: The next generation of antimalarial drugs?;Cell Chemical Biology;2023-05